Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors

American Journal of Surgical Pathology

Volumn 39, Issue 5, 2015, Pages 592-601

  Kim, Joo Young ^a,c   Kim, Min Sun ^b   Kim, Ki Suk ^d   Song, Ki Byung ^a   Lee, Seung Hun ^a   Hwang, Dae Wook ^a   Kim, Kyu Pyo ^a,b   Kim, Hyoung Jung ^a   Yu, Eunsil ^a,b   Kim, Song Cheol ^a,b   Jang, Hyeung Jin ^d   Hong, Seung Mo ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c College of Medicine   (South Korea)

^d Kyung Hee University   (South Korea)

Author keywords

gastrin; glucagon; glucagon like peptide 1; hormone; insulin; neuroendocrine tumor; pancreas; prognosis; serotonin; somatostatin

Indexed keywords

PEPTIDE HORMONE;

ADOLESCENT; ADULT; AGED; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PEPTIDE HORMONES; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84928589832     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000383     Document Type: Article

References (35)

1. Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008;95:627-635.
2. Tsutsumi K, Ohtsuka T, Mori Y, et al. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012; 47:678-685.
3. Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766-1773.
4. Jarufe NP, Coldham C, Orug T, et al. Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment. Dig Surg. 2005;22:157-162.
5. Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg. 2006;10:327-331.
6. Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490-500.
7. Kapran Y, Bauersfeld J, Anlauf M, et al. Multihormonality and entrapment of islets in pancreatic endocrine tumors. Virchows Arch. 2006;448:394-398.
8. Heitz PU, Kasper M, Polak JM, et al. Pancreatic endocrine tumors. Hum Pathol. 1982;13:263-271.
9. Le Bodic MF, Heymann MF, Lecomte M, et al. Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia, type I. Am J Surg Pathol. 1996;20:1378-1384.
10. Liu TH, Tseng HC, Zhu Y, et al. Insulinoma. An immunocytochemical and morphologic analysis of 95 cases. Cancer. 1985;56: 1420-1429.
11. Mukai K, Grotting JC, Greider MH, et al. Retrospective study of 77 pancreatic endocrine tumors using the immunoperoxidase method. Am J Surg Pathol. 1982;6:387-399.
12. Bosnan FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer; 2010.
13. Liu TH, Zhu Y, Cui QC, et al. Nonfunctioning pancreatic endocrine tumors. An immunohistochemical and electron microscopic analysis of 26 cases. Pathol Res Pract. 1992;188:191-198.
14. Zheng X, Guo K, Tian Y, et al. Cellular composition and anatomic distribution in nonfunctioning pancreatic endocrine tumors: immunohistochemical study of 30 cases. Chin Med J (Engl). 1998;111: 373-376.
15. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199-1203.
16. Krausch M, Raffel A, Anlauf M, et al. Loss of PTEN expression in neuroendocrine pancreatic tumors. Horm Metab Res. 2011;43: 865-871.
17. Marinoni I, Kurrer AS, Vassella E, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146:453-460. e455.
18. Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol. 1996;10:342-355.
19. Edge SB, Byrd DR, Compton CC, et al. The AJCC Cancer Staging Manual. 7th Ed. New York, NY: Springer; 2010.
20. McCall CM, Shi C, Klein AP, et al. Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement. Hum Pathol. 2012; 43:1169-1176.
21. Delellis RA, Lloyd RV, Heitz PU, et al. World Helath Organization Classification of Tumours Pathology and Genetics of Tumours of Endocrine Organs. Lyon: International Agency for Research on Cancer; 2004.
22. Phan GQ, Yeo CJ, Hruban RH, et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg. 1998;2:473-482.
23. Han X, Xu X, Jin D, et al. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single chinese center. Pancreas. 2014;43:526-531.
24. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633-2642.
25. Holst JJ. Glucagon and glucagon-like peptides 1 and 2. Results Probl Cell Differ. 2010;50:121-135.
26. Vangoitsenhoven R, Mathieu C, Van der Schueren B. GLP1 and cancer: friend or foe? Endocr Relat Cancer. 2012;19: F77-F88.
27. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-156.
28. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology. 2003;144:5145-5148.
29. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003; 30:781-793.
30. Cases AI, Ohtsuka T, Fujino M, et al. Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors. Pancreas. 2014;43:1-6.
31. Soga J, Yakuwa Y. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg. 1998;5:77-85.
32. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469-1492.
33. Imamura M, Kanda M, Takahashi K, et al. Clinicopathological characteristics of duodenal microgastrinomas. World J Surg. 1992; 16:703-709; discussion 709-710.
34. Pipeleers-Marichal M, Donow C, Heitz PU, et al. Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J Surg. 1993; 17:481-488.
35. Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer. 2008;15: 229-241.